Objective To explore the level and influencing factors of serum procalcitonin (PCT) in maintenance hemodialysis (MHD) patients, and to evaluate the diagnostic value of PCT for infections in MHD patients. Methods A total of 500 MHD patients without clinical infection were selected in this cross-sectional study. They were further stratified according to serum PCT level. The influencing factors for the higher serum PCT in MHD patients were investigated by inter-group comparison, univariate and multivariate logistic regression analyses. Additionally, a total of 115 MHD patients with clinical infections were recruited. The optimal cut-off value of serum PCT for the diagnosis of infections in the MHD patients was determined by receiver operating characteristic (ROC) curve and the area under the curve (AUC). Results Compared with non-infected groups,serum PCT was significantly elevated in patients in the infected group (Z=-14.204, P＜0.001). Logistic regression showed that catheters as the dialysis access (OR=2.142, 95% CI:1.282~3.579, P=0.004), male (OR=1.517, 95% CI: 1.036~2.221, P=0.032), hemoglobin＜110g/L (OR=1.792, 95% CI 1.225~2.623, P=0.003), blood phosphorus≥1.78mmol/L (OR=1.608, 95% CI:1.079~2.379, P=0.020) and parathyroid hormone >300pg/ml (OR=1.693, 95% CI:1.156~2.479, P=0.007) were the independent risk factors for higher serum PCT level in MHD patients. When the cut-off value of serum PCT was set at 0.851ng/ml, the sensitivity and specificity of PCT to predict infections in MHD patients were 85.2% and 87.2% respectively, with the AUC of 0.924 (95% CI 0.896~0.953). Conclusions Serum PCT is significantly increased in MHD patients. We recommend a higher diagnostic threshold of serum PCT for the clinical diagnosis of infections in MHD patients.
[1] 芦倩倩, 常沁涛, 方敬爱, et al. 维持性血液透析患者微炎症状态的研究进展[J]. 中国血液净化, 2021, 20(7): 483-485.
[2] 张欣悦, 王琛. 降钙素原在慢性肾脏病中的研究进展[J]. 中国临床医生杂志, 2022, 50(1): 36-40.
[3] 降钙素原急诊临床应用专家共识组. 降钙素原(PCT)急诊临床应用的专家共识[J]. 中华急诊医学杂志, 2012, 21(9): 944-951.
[4] 中国医药教育协会感染疾病专业委员会. 降钙素原指导抗菌药物临床合理应用专家共识[J]. 中华医学杂志, 2020, 100(36): 2813-2821.
[5] Kubo S, Iwasaki M, Horie M, et al. Biological variation of procalcitonin levels in hemodialysis patients[J]. Clin Exp Nephrol, 2019, 23(3): 402-408.
[6] Wu S C, Liang C X, Zhang Y L, et al. Elevated serum procalcitonin level in patients with chronic kidney disease without infection: A case-control study[J]. J Clin Lab Anal, 2020, 34(2): e23065.
[7] 中华医学会重症医学分会. 血管内导管相关感染的预防与治疗指南(2007)[J]. 中华内科杂志, 2008, 47(8): 691-699.
[8] Gupta K, Hooton T M, Naber K G, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases[J]. Clin Infect Dis, 2011, 52(5): e103-20.
[9] Farthing M, Salam M A, Lindberg G, et al. Acute diarrhea in adults and children: a global perspective[J]. J Clin Gastroenterol, 2013, 47(1): 12-20.
[10] 社区获得性肺炎诊断和治疗指南[J].中华结核和呼吸杂志, 2006(10): 651-655.
[11] 中国医师协会肾脏内科医师分会肾性贫血指南工作组. 中国肾性贫血诊治临床实践指南[J]. 中华医学杂志, 2021, 101(20): 1463-1502.
[12] 王莉, 李贵森, 刘志红. 中华医学会肾脏病学分会《慢性肾脏病矿物质和骨异常诊治指导》[J]. 肾脏病与透析肾移植杂志, 2013, 22(6): 554-559.
[13] Trimarchi H, Dicugno M, Muryan A, et al. Pro-calcitonin and inflammation in chronic hemodialysis[J]. Medicina (B Aires), 2013, 73(5): 411-6.
[14] Demir N A, Sumer S, Celik G, et al. How should procalcitonin and C-reactive protein levels be interpreted in haemodialysis patients?[J]. Internal Medicine Journal, 2018, 48(10): 1222-1228.
[15] Herget-Rosenthal S, Klein T, Marggraf G, et al. Modulation and source of procalcitonin in reduced renal function and renal replacement therapy[J]. Scand J Immunol, 2005, 61(2): 180-6.
[16] Meisner M, Lohs T, Huettemann E, et al. The plasma elimination rate and urinary secretion of procalcitonin in patients with normal and impaired renal function[J]. Eur J Anaesthesiol, 2001, 18(2): 79-87.
[17] 米慧, 陈江伟, 李宗英, et al. 降钙素原在非感染性疾病中的研究进展[J]. 检验医学与临床, 2018, 15(18): 2821-2824.
[18] Conti G, Amore A, Chiesa M, et al. Procalcitonin as a marker of micro-inflammation in hemodialysis[J]. J Nephrol, 2005, 18(3): 282-8.
[19] Colì L, Donati G, Cappuccilli M L, et al. Role of the hemodialysis vascular access type in inflammation status and monocyte activation[J]. Int J Artif Organs, 2011, 34(6): 481-8.
[20] Sachdeva M, Hung A, Kovalchuk O, et al. The initial vascular access type contributes to inflammation in incident hemodialysis patients[J]. Int J Nephrol, 2012, 2012: 917465.
[21] 赵璐, 刘虹. 慢性肾脏病患者的炎症状态及其对肾性贫血治疗的影响[J]. 中国血液净化, 2020, 19(3): 149-152.
[22] 司倩楠. 维持性血液透析患者微炎症状态与肾性贫血的相关性分析[D]. 新乡医学院, 2020.
[23] Level C, Chauveau P, Delmas Y, et al. Procalcitonin: a new marker of inflammation in haemodialysis patients?[J]. Nephrol Dial Transplant, 2001, 16(5): 980-6.
[24] 魏娜, 沈学飞, 常万松, et al. 甲状旁腺激素对维持性血液透析患者调节性T细胞和微炎症的影响[J].医药论坛杂志, 2013, 34(02): 29-30+33.
[25] 付晓静, 黎银崧. 甲状旁腺全切+前臂移植术对继发严重甲状旁腺功能亢进患者微炎症和胰岛素抵抗的影响[J].中国血液净化, 2019, 18(05): 291-294.
[26] 林兴芳, 李斌, 姬珊珊. 碳酸司维拉姆联合高通量血液透析对尿毒症患者钙磷代谢及微炎症状态的影响[J]. 国际医药卫生导报, 2020, 26(3): 326-328.
[27] 沈裕欣, 王扬扬, 邓文艳, et al. 慢性肾脏病合并心功能不全患者微炎症因子、钙磷代谢水平变化及临床意义[J]. 中国医药导报, 2022, 19(1): 102-105.
[28] Lee W S, Kang D W, Back J H, et al. Cutoff value of serum procalcitonin as a diagnostic biomarker of infection in end-stage renal disease patients[J]. Korean J Intern Med, 2015, 30(2): 198-204.
[29] Sun Y, Jiang L, Shao X. Predictive value of procalcitonin for diagnosis of infections in patients with chronic kidney disease: a comparison with traditional inflammatory markers C-reactive protein, white blood cell count, and neutrophil percentage[J]. Int Urol Nephrol, 2017, 49(12): 2205-2216.
[30] Dumea R, Siriopol D, Hogas S, et al. Procalcitonin: diagnostic value in systemic infections in chronic kidney disease or renal transplant patients[J]. Int Urol Nephrol, 2014, 46(2): 461-8.
[31] Tao M, Zheng D, Liang X, et al. Diagnostic value of procalcitonin for bacterial infections in patients undergoing hemodialysis: a systematic review and meta-analysis[J]. Ren Fail, 2022, 44(1): 81-93.
[32] 孙妍蓓, 蒋丽娟, 邵小南. 降钙素原对慢性肾脏病5期患者感染的预测价值[J]. 东南大学学报（医学版）, 2018, 37(4): 553-559.
